# A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease

> **NCT04520412** · PHASE3 · SUSPENDED · sponsor: **Green Valley (Shanghai) Pharmaceuticals Co., Ltd.** · enrollment: 2046 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** GV-971
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04520412
- **Lead sponsor:** Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-10-27
- **Primary completion:** 2025-12
- **Final completion:** 2026-10
- **Target enrollment:** 2046 (ESTIMATED)
- **Why stopped:** The quality of study was seriously affected by the COVID-19, so it was decided to suspend the trial and restart it at the right time.
- **Last updated:** 2022-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04520412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04520412, "A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04520412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*